Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback